Rigel Pharmaceuticals Charts Course Toward Profitability

Rigel US7665596034

Rigel Pharmaceuticals is positioning itself for a potentially transformative 2026, with leadership changes and strong preliminary financials setting the stage. The central question for investors is whether the company's clinical pipeline can sustain this momentum.

• Financial Preview: Preliminary fourth-quarter revenue reached approximately $69.8 million.
• 2026 Outlook: The company forecasts total revenue between $275 and $290 million, targeting its first net profit.
• Governance Move: Industry veteran Michael P. Miller has been appointed to the Board of Directors.
• Upcoming Event: Audited full-year 2025 results are scheduled for release on March 3.

The operational data reveals a positive trend. Preliminary figures released in mid-January indicate fourth-quarter 2025 revenue of about $69.8 million. This represents a significant increase from the $57.6 million reported for the same period a year earlier.

For the current fiscal year 2026, management has provided revenue guidance in the range of $275 million to $290 million. A key component of this forecast is Rigel's expectation to achieve a positive net income for the first time in 2026. The company ended the year with a cash position of roughly $154.6 million, which appears sufficient to fund its clinical programs in the near term.

Board Expansion with Commercial Expertise

In a strategic move to bolster its commercial capabilities, Rigel announced the appointment of Michael P. Miller to its Board of Directors this Tuesday. Miller brings more than four decades of leadership experience from prominent roles at Jazz Pharmaceuticals and Genentech. This appointment underscores the firm's commitment to enhancing its market execution.

Ahead of the imminent annual results, analyst sentiment remains cautious. The current consensus rating among covering brokerages continues to be "Hold." Market observers are evidently awaiting the detailed financial disclosures before revising their assessments.

Clinical Pipeline Progress

The long-term investment thesis for Rigel continues to hinge on its drug candidate R289 for treating myelodysplastic syndromes (MDS). Patient recruitment for the ongoing expansion phase of the Phase 1b study is proceeding according to plan. Rigel aims to identify the optimal dosage for the pivotal Phase 2 study in the second half of 2026.

Initial data from this phase is anticipated by year-end. Earlier results from the dose-escalation study have been promising: approximately 33% of treated patients receiving a daily dose of at least 500 mg achieved transfusion independence for a minimum of eight weeks.

The foundation for achieving this year's profitability goals will be set when Rigel presents its final, audited figures for the full year 2025 on March 3.

@ boerse-global.de | US7665596034 RIGEL